Yin, Jiale, Author at MediaMedic

Current status of diagnosis and treatment of chronic lymphocytic leukemia in China: A nationalmulticenter survey research

By Yin, Jiale 2024.02.23

Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published in May 2023 in the Chinese Journal of Hematology titled "Current status of diagnosis and treatment of chronic lymphocytic leukemia in…

Efficacy and safety of mitoxantrone hydrochloride liposome injection in treatment of peripheral T-celllymphomas: a multicenter, non-interventional, ambispective cohort, real-world study (MOMENT)

By Yin, Jiale 2024.02.23

In August 2023, Professor Jun Ma and his team from Harbin Institute of Hematology Oncology published a paper in the Journal of Leukemia & Lymphoma titled "Efficacy and safety of mitoxantrone hydrochloride…

Efficacy and Safety of Crovalimab in Complement Inhibitor-Naive Patients with PNH

By Yin, Jiale 2024.02.20

In September 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— American Journal of Hematology(IF=13.268). The title of the…

Immunogenic Cell Death in Hematological Malignancy Therapy

By Yin, Jiale 2024.02.20

In May 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Adv Sci (Weinh) (IF=17.521). The title of the study…

Gene Therapy Using BCMA/CD3 Bispecific Antibody-Encoding Plasmid DNA: A Novel Approach for Treating Multiple Myeloma

By Yin, Jiale 2024.02.20

In May 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— British Journal of Haematology(IF=8.615). The title of the…

BSA-AIE Nanoparticles for Immunogenic Cell Death Immunotherapy of Multiple Myeloma

By Yin, Jiale 2024.02.20

In February 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Advanced Materials(IF=32.086). The title of the study is…

Unveiling the Role of BMSCs in NK Cell Exhaustion via the Tim-3/Galectin-9 Pathway in Multiple Myeloma

By Yin, Jiale 2024.02.20

In March 2023, a study led by Professor Rong Fu from Tianjin Medical University General Hospital was published in the prestigious international academic journal —— Clinical And Translational Medicine(IF=10.6). The title of the study…

Polatuzumab Vedotin Enhances Treatment Efficacy in Previously Untreated DLBCL: Insights from the Asia Subpopulation of the POLARIX Trial

By Yin, Jiale 2024.02.07

In April 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood (IF=25.669). The title of the study is "Polatuzumab…

$Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study$

Comprehensive Analysis of Orelabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma: A Phase 1/2 Study

By Yin, Jiale 2024.02.07

In August 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——Blood Advances (IF=7.642). The title of the study is "Orelabrutinib for…

$Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study$

Orelabrutinib for the Treatment of Relapsed or Refractory Marginal Zone Lymphoma: A Phase 2 Study

By Yin, Jiale 2024.02.07

In November 2023, a study led by Professor Jun Zhu from Peking University Cancer Hospital and Institute was published in the prestigious international academic journal ——American Journal of Hematology (IF=12.8). The title of…